Jupiter Neurosciences

Jupiter Neurosciences is a private, clinical-stage company founded in 2019, developing novel oral therapies targeting neuroinflammation. Its lead platform, JOTROL™, is a patented micellar formulation of resveratrol designed to overcome poor bioavailability and enable therapeutic dosing for central nervous system disorders. The company's strategy involves a dual-path pipeline, with a long-term focus on Alzheimer's disease and parallel development in rare, orphan neurological indications. Jupiter appears to be pre-revenue and is likely funded by private investment as it advances its programs.

JOTROL™, a patented oral micellar formulation designed to significantly enhance the bioavailability and blood-brain barrier penetration of resveratrol, enabling its therapeutic use for neuroinflammation.

In Alzheimer's, Jupiter competes with large pharma and biotechs targeting amyloid, tau, and inflammation via various modalities. In rare diseases, competition comes from targeted therapies. JOTROL's key differentiator is its oral delivery aiming to solve resveratrol's bioavailability challenge.